Anti-cxcr3 antibodies
AssigneeGenzyme Corporation
InventorsMichele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
Claims49
An antibody or antigen binding fragment capable of binding to CXCR3, wherein the antibody or fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein:
- a) the heavy chain variable region comprises three complementarity determining regions (CDRs) that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 2, 4, 6, and 8;
- and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 3, 5, 7, and 9,
- b) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 10, 12, 14, and 16;
- and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 11, 13, 15, and 17,
- c) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 18, 20, 22, 24, and 26-33;
- and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 19, 21, 23, 25, and 34-37,
- d) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ. ID NO:
- 38, 40, 42, 44, 46-48, and 63-66;
- and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 39, 41, 43, 45, 49-54, and 67-70, or
- e) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 55, 57, 59, and 61;
- and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO:
- 56, 58, 60, and 62.
An antibody or antigen binding fragment capable of binding to CXCR3, wherein the antibody or fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein:
- a) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 2, 4, 6, and 8;
- and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 3, 5, 7, and 9,
- b) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 10, 12, 14, and 16;
- and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 11, 13, 15, and 17,
- c) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 18, 20, 22, 24, and 26-33;
- and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 19, 21, 23, 25, and 34-37,
- d) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 38, 40, 42, 44, 46-48, and 63-66;
- and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 39, 41, 43, 45, 49-54, and 67-70, or
- e) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 55, 57, 59, and 61;
- and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO:
- 56, 58, 60, and 62.
The pharmaceutical composition of claim 47, wherein the at least one additional therapeutic agent comprises a n-cell stimulating agent, insulin, or an insulin-producing cell.
Dependencies are inferred from the claim text.